Efforts to develop immune-based therapies for HIV infection have been impeded by incomplete definition of the immunological correlates of protection. Despite many precedents demonstrating that CD8 + cytotoxic T lymphocytes are key mediators of protective anti-viral immunity in non-human animal models, direct evidence that these effector cells control viral replication in HIV-1 infection has remained elusive. The first part of this paper describes a detailed immunological and genetic study founded on evolutionary considerations. Following infection with HIV-1, virus variants which escaped recognition by autologous cytotoxic T lymphocytes were shown to possess a selection advantage within the host environment. Cytotoxic T lymphocytes therefore exert anti-viral pressure in vivo. This observation provides compelling evidence that cytotoxic T lymphocytes comprise a significant element of antiretroviral immunity. Subsequently, the quantification of peripheral cytotoxic T lymphocyte frequencies utilizing peptide-(human leucocyte antigen class I) tetrameric complexes is described. Five patients with qualitatively similar immunodominant cytotoxic T lymphocyte responses during symptomatic primary HIV-1 infection were studied longitudinally. Expansions of virus-specific CD8 + lymphocytes comprising up to 2 % of the total CD8 + T cell population were observed in the acute phase of infection. Antigenic load was identified as an important determinant of circulating HIV-1-specific CD8 + lymphocyte levels ; however, significant numbers of such cells were also found to persist following prolonged therapeutic suppression of plasma viraemia. In addition, an analysis of antigenic sequence variation with time in this case series suggests that the early administration of combination anti-retroviral therapy may limit HIV-1 mutational escape from host cytolytic specificities. The implications of these preliminary data are discussed. The data presented suggest that vaccination protocols should aim to elicit vigorous cytotoxic T lymphocyte responses to HIV-1. Attempts to stimulate polyvalent responses to mutationally intolerant epitopes are likely to be most effective. Optimal management of HIV-1 infection requires an understanding of dynamic host-virus interactions, and may involve strategies designed to enhance cytotoxic T lymphocyte activity following periods of antiretroviral drug therapy.
INTRODUCTION
More than 30 million people worldwide are currently infected with HIV, and there are an estimated 16 000 new cases daily [1] . The scale of this global pandemic has expedited the production of potent anti-retroviral drugs with the capacity to modify the natural history of HIV infection. However, with the major burden of disease concentrated in sub-Saharan Africa and South East Asia, the delivery of expensive therapeutic regimens to infected individuals remains limited [2] . Much research therefore continues to focus on the development of effective vaccination strategies ; clear definition of the correlates of protective immunity against HIV infection is an essential prelude to the rational design of such interventions. The work outlined in this paper forms part of this effort, and represents an attempt to further present understanding of the virus-specific CD8 + cytotoxic T lymphocytes (CTL) response in HIV-infected individuals.
ARE CTL IMPORTANT IN PRIMARY HIV-1 INFECTION ? Background
Since the initial descriptions of virus-specific CTL in HIV-1-infected individuals [3, 4] , the significance of these effector cells in vivo has remained controversial [5, 6] . It is established that HIV-1-specific CTL emerge early following infection, and that this activity is temporally coincident with suppression of the initial viraemia [7, 8] . Subsequently, virus-specific CTL commonly persist in high numbers throughout the asymptomatic phase, and then decline with progression to disease [9] [10] [11] [12] [13] [14] [15] . Further, in vitro experiments have demonstrated that CTLmediated target cell lysis is sufficiently rapid to kill HIV-1-infected lymphocytes before progeny virions are produced [16] . However, despite implication by association, there has been no direct evidence that naturally generated CTL activity can modulate the course of HIV-1 infection ; such demonstrations form the basis on which CTL have been identified as primary mediators of Arrows indicate separation of coding sequences in the linear 9.8 kb RNA genome ; splicing is required to generate functional mRNA. Individual recombinant vaccinia virus constructs encoding the major structural proteins Gag, Pol and Env, and the regulatory protein Nef, were used to determine the origin of immunodominant CTL epitopes. Responses to peptide fragments derived from minor proteins, or to epitopes from the major proteins of individual infecting strains with amino acid sequences distinct from those of the consensus vaccinia inserts, were not excluded. Abbreviations : IN, integrase ; LTR, long terminal repeat ; PR, protease ; RNH, RNaseH ; RT, reverse transcriptase.
protective anti-viral immunity in experimental infections of non-human animals [17] . In addition, viral turnover remains high throughout the course of infection [18] [19] [20] [21] , and progression to AIDS occurs despite an often potent CTL response. These observations have been interpreted as being inconsistent with a protective role for CTL in HIV-1 infection [22, 23] .
The approach described here exploits evolutionary considerations to investigate the influence of host CTL activity on the virus population [20, 21, [24] [25] [26] [27] . In essence, if CTL comprise a significant element of anti-retroviral immunity, then viral forms that escape the dominant cytolytic specificity should possess a survival advantage in vivo.
Specificity of early CTL responses
Surface interactions between the T cell receptor (TCR) and peptides of 8-11 amino acids (epitopes) bound to major histocompatibility complex (MHC) class I molecules form the basis for CTL recognition of cells expressing foreign or dysfunctional proteins. Peptide epitopes are generated primarily by proteolytic cleavage in the cytosol, and associate with MHC class I molecules in the endoplasmic reticulum prior to externalization [28] . Virally infected cells thus present an array of nonself epitopes capable of stimulating specific CTL responses. In order to map the specificity of a CTL response within an individual, it is therefore necessary to determine the viral protein from which the epitope originated (Figure 1 ), identify the restricting MHC class I molecule and refine the optimal antigenic sequence with overlapping peptides [29] . This final step is facilitated in practice by the prediction of likely epitope sequences from published motifs [30] .
Freshly isolated peripheral blood leucocytes (PBL) restimulated with autologous virus in vitro (bulk cultured lymphocytes) were used as effector cells in standard &"Cr release cytolysis assays to determine the patterns of CTL reactivity in patients with symptomatic primary HIV-1 infection. In each of five such patients with the human leucocyte antigen (HLA) B8 allele, strong early responses were identified to the HLA B8-restricted epitope Table 1 Serial lymphocyte subset counts and plasma HIV-1  RNA loads from patient SC2 This 36-year-old homosexual male presented with a sore throat, fever, headache and photophobia. A serological screen for anti-HIV-1 antibodies performed 9 months earlier had been negative. Serum sampled on admission tested positive for HIV-1 p24 antigen ( 100 pg/ml) and negative for anti-HIV-1 antibodies. A second sample obtained 6 days later tested positive for HIV-1 p24 antigen ( 500 pg/ml), positive for antibodies against HIV-1 gp41, and negative for antibodies against HIV-1 p24, p17 and gp36. Subsequent serum samples were consistently HIV-1 p24 antibody positive. HLA class I genotype : A1/k, B7/8, Cw0701/0702. Abbreviation : ND, not done.
Lymphocyte subset counts (i10 6 Later samples from SC2, who declined anti-retroviral therapy (ART) at presentation and remained untreated for more than 500 days, also exhibited cytolytic activity with this specificity. Additional responses were not detected in patients SC10, SC11, SC12 and SC17 following the early initiation of ART.
Viral antigenic variation
The clinical and laboratory data from patient SC2 are summarized in Table 1 . This patient's decision to defer treatment following diagnosis provided an opportunity to study the relationship between CTL activity and viral diversification during seroconversion in the absence of iatrogenic intervention. Proviral nef present in DNA extracted from uncultured PBL was amplified with a nested polymerase chain reaction ; the products were cloned and sequenced using standard techniques [31] . An expansion of coding mutations was observed in the epitope region after the onset of detectable FLKEKGGLspecific cytolytic activity at 22 days following the onset of symptoms (22 DFOSx) ( Figure 2 ). Importantly, this segment of the proviral genome was invariant over time in control subjects with primary HIV-1 infection who lacked the HLA B8 allele [31] . Phenotypic characterization of these variant epitopes demonstrated that the prevalent mutants were suboptimal ligands for auto- A number of clones contained frameshifts or truncations that resulted in failure to encode this HLA B8-restricted Nef epitope [31] . Variant residues are shown in bold type.
logous CTL in terms of functional outcome ( Figure 3 ). The original proviral population had therefore been largely superseded by variant forms incorporating CTL escape sequences. An analysis of epitope variation in the context of viral genetic diversity was undertaken in an attempt to exclude the possibility that these changes reflected a linkage phenomenon unrelated to immune selection pressures.
Positive selection of CTL escape variants
The ratio of the rates of non-synonymous (coding) and synonymous (silent) nucleotide substitutions (dN\dS) was used to assess selection intensity across a region of the nef gene incorporating the FLKEKGGL epitopeencoding sequence [32] (Figure 4) . In broad terms, synonymous substitutions are detected more commonly than non-synonymous changes ; this reflects negative selection favouring the conservation of protein structure The FLKEKGGL-specific response was initially detected in a peptide-based assay at 22 DFOSx [31] ; subsequent retrospective screening of cryopreserved bulk cultured lymphocytes with recombinant vaccinia virus constructs expressing HIV-1 proteins (see Figure 1 ) failed to identify additional cytolytic specificities at this time. (A) Standard 51 Cr release cytotoxicity assay with HLA B8-matched Epstein-Barr virus immortalized B cell targets. Synthetic peptides were used to represent epitope variants at the concentrations shown. (B) Functional HLA B8 binding assay. Target cells were pulsed for 1 h with 10 µM peptide at 1.5, 5, 10, 16 and 24 h prior to assay, then washed twice and incubated in fresh medium until labelling with 51 Cr immediately before the experiment. The dominant variants with mutations at the HLA B8 anchor position 5 exhibit impaired recognition when pulsed on to targets more than 1 h before assay, suggesting rapid dissociation from the restricting class I molecule. This may be especially relevant to the 5Q variant, which is recognized as an agonist ligand when present on the target cell surface (A). Functional binding assays are limited by differing dose-response relationships between variants (A) ; however, similar results in terms of binding hierarchy were observed with these variants in HLA B8 protein assembly assays [29] . The ratio of CTL to targets was 10 : 1 in both assays. and function. A dN\dS value of 1 indicates positive selection. Strong evidence for positive selection localized to the antigenic sequence was obtained with a sliding window modification of this technique [31, 33] (Figure 4 ). In addition, variation at the protein level was confined largely to the epitope ( Figure 4 ).
Discussion
Naturally occurring HIV-1 epitope variants that impair CTL recognition have been described previously [35, 36] , but the relevance of these mutations has remained uncertain. In common with other RNA viruses, HIV-1 replicases lack proof-reading capacity [25, 26] . This property combines with rapid replication rates to generate a genetically diverse viral population, or quasi-species, in vivo [37] . Immune escape mutations may therefore be present by chance. However, due to the extreme genetic instability of HIV-1, adaptive evolution within the individual host environment is a feature of infection [27] . This phenomenon was central to the rationale of the work presented.
If CTL are important in limiting viral replication, then evidence of this effect should be apparent during a period of intense CTL activity on a large viral population. Such conditions are present during primary HIV-1 infection, in which an early massive viraemia declines in conjunction with the emergence of a virus-specific CTL response [7, 8, 38, 39] . In addition, restricted antigen specificity may be a characteristic of the acute CD8 + lymphocyte expansions observed in primary HIV-1 infection [40, 41] ; this peculiarity of the initial CTL response could facilitate immune escape [42, 43] . These considerations determined patient selection.
The key finding of this project was that CTL escape mutations in HIV-1 confer a selection advantage in vivo. This indicates that CTL exert anti-viral pressure under the conditions of natural HIV-1 infection, thereby providing strong evidence that such effector cells comprise a significant element of anti-retroviral immunity. Similar results were documented in a parallel study of a seroconverter with a dominant HLA B44-restricted CTL response to an epitope in HIV-1 Env [44] . It is tempting to speculate that CTL escape events underlie the failure of cellular immunity to control HIV-1 infection [15, 45] .
ARE EARLY CTL RESPONSES AFFECTED BY TREATMENT ? Background
The advent of anti-retroviral drugs has provided the opportunity for therapeutic intervention in HIV-1-infected individuals. While evolutionary considerations demand the co-administration of multiple agents [46] , the potency of these drugs in combination can dramatically attenuate the natural history of HIV-1 infection. However, prolonged ART is associated with significant side effects, and rebound viraemia is almost invariable following the discontinuation of treatment initiated in established infection. Interest has therefore focused on [34] . (B) The rates of synonymous (dS ; broken lines) and non-synonymous (dN ; solid lines) substitutions were calculated in a sliding window of 60 nucleotides over all pairwise comparisons between clones at each time point ; this procedure was repeated in single-codon increments. Values are plotted against the central nucleotide in the window. Positive selection (dN dS ) localized to the epitope-encoding region is apparent at 110 and 172 DFOSx ; the FLKEKGGL-specific CTL response was initially detected at 22 DFOSx. The apparent extension of positive selection beyond the limits of the epitope is a methodological artefact that reflects window width, not non-synonymous nucleotide substitutions in the flanking regions. Clones in which truncations or frameshifts resulted in epitope deletion were excluded from this analysis for technical reasons ; their presence provides further evidence for CTL-mediated positive selection in this case [31] .
the use of combination therapy in individuals presenting with clinical manifestations of acute seroconversion to HIV-1 [47] . Early-treatment policies have been adopted widely, although currently there is no evidence of benefit in terms of either clinical outcome or prognostic indicators. The work described here forms part of an investigation into the immunological and virological perturbations associated with early interruption of viral replication.
Peptide-(HLA class I) tetrameric complexes
The recent development of soluble fluorochromelabelled peptide-(HLA class I) tetrameric complexes has allowed direct ex vivo quantification of T cells bearing receptors specific for defined antigens ( Figure 5 ). This method obviates requirements for cellular expansion in vitro and measurement of functional responses dependent on antigen encounter, and represents a significant technical advance in the study of cellular immunity [11, [48] [49] [50] . The detection of qualitatively similar immunodominant CTL responses in five patients with primary HIV-1 infection provided a cohort amenable to study with identical tetrameric reagents ( Figure 6 ).
Longitudinal quantification of antigenspecific CD8 + lymphocytes
The clinical features and virus loads of patients SC10, SC11, SC12 and SC17 are summarized in Figure 7 . During the acute phase, 0.5-2 % of total peripheral blood CD8 + lymphocytes were specific for the HLA B8- Figure 7 ). These numbers represent large antigenspecific expansions within the CD8 + lymphocyte population, and are comparable with results obtained during the acute-phase response in other viral infections [48] . Following the initiation of ART, the frequency of Nefspecific CD8 + lymphocytes increased transiently ( Figure  7 ). The processes underlying this phenomenon are unclear, although both enhanced proliferation and redistribution of virus-specific CD8 + T cells from lymphoid tissue to peripheral blood may be involved [51] . After these early fluctuations, levels of Nef-specific CD8 + lymphocytes paralleled virus load ; consistent declines were observed with effective suppression of viraemia, and increased frequencies accompanied viral rebound following the discontinuation of ART (Figure 7 ). In contrast, minimal variation was observed in the numbers of CD8 + lymphocytes staining with control tetramers specific for HLA B8-restricted epitopes in Epstein-Barr virus and influenza virus, indicating that cellular immunity is not impaired directly by ART. These data suggest that antigenic load is an important determinant of peripheral virus-specific CD8 + lymphocyte frequencies, and are compatible with previous experiments in murine systems [52] .
Interestingly, however, Nef-specific CD8 + lymphocytes were detectable to the end of the study period in patients SC10 and SC12, despite prolonged suppression of plasma viraemia with continued treatment (Figure 7) . Factors contributing to the persistence of these antigen-specific cells may include continued viral replication at low levels and sustained helper functions provided by HIV-1-specific CD4 + lymphocyte responses preserved by therapeutic reduction of virus load early in infection [53] . Preliminary studies with monoclonal antibodies specific for surface markers associated with cellular activation demonstrated phenotypic heterogeneity within these Nef-specific CD8 + lymphocyte populations (Figure 8 ). Further data are required to determine the relationship between antigen dependence, CD8 + lymphocyte phenotype and effector function during the evolution of a specific immune response to viral infection [57] .
Antigenic integrity and therapeutic intervention
Frequencies of FLKEKGGL-specific CD8 + lymphocytes defined by tetramer staining declined with time in patient SC2 (Figure 7 ). This was associated with the emergence of epitope variants which escaped recognition by autologous CTL [31] (Figures 2-4) . Therefore, despite a persistent viraemia of almost 10' copies\ml of plasma, the proposal that at least a subpopulation of virusspecific CD8 + lymphocytes is maintained by persistent antigenic drive still applies due to qualitative changes in the immunogenic epitope. These immune escape variants persisted within the residual virus population after subsequent therapeutic suppression of viraemia from 586 DFOSx (12\16 variant clones at 606 DFOSx ; 13\18 variant clones at 718 DFOSx). A similar decline in CD8 + lymphocytes quantified with the WPTVRERM tetramer was also associated with variation in the epitopeencoding region (results not shown). In contrast, no accumulation of variants over time was observed within the FLKEKGGL-epitope-encoding region in the treated patients, and formal analysis showed no evidence of positive selection for mutations localizing to antigenic loci (results not shown). These data suggest that, in the presence of a defined, immunodominant CTL response, antigenic variation in the persisting proviral population may be limited under conditions of restricted viral replication.
There are a number of possible explanations for this apparent antigenic stasis in treated patients. First, despite the large numbers of apparently immunodominant Nefspecific CD8 + lymphocytes in patients SC10, SC11 and SC12, it is possible that the optimal conditions required for positive selection of escape variants were not met in these patients. The interactions between CTL and a variable virus necessary for selection to occur are dependent on a number of factors, including the size and Cytotoxic T lymphocytes in primary HIV-1 infection Representative fluorescence-activated cell sorting data from patients SC10 (71 DFOSx), SC11 (32 DFOSx), SC12 (30 DFOSx) and SC17 (36 DFOSx). Antigen-specific CD8 + lymphocytes are visualized in the upper right quadrant. Levels of tetramer staining correlated positively with cytolytic activity in 51 Cr release assays. Negative controls comprised HLA B8-positive uninfected subjects and HLA B8-negative patients with primary HIV-1 infection ; cryopreserved and fresh PBL samples obtained from these donors consistently stained to less than 0.05 % of the total CD8 + lymphocyte population with both the FLKEKGGL and WPTVRERM tetramers. The five patients recruited to this study acquired HIV-1 through high-risk sexual encounters, and presented with typical seroconversion illnesses comprising fever, rash and lymphadenopathy. Additional clinical features included meningism in SC2 (see Table 1 ), parasthesiae and oral candidiasis in SC11, anorexia in SC12 and nausea in SC17. Primary infection in these patients was defined as the presence of HIV-1 RNA or p24 antigen during the acute illness, with a negative antibody test within the previous 6 months. Total CD8 + lymphocyte counts were elevated during the acute illness, and returned to baseline levels within a period of approx. 1 month (results not shown). The WPTVRERM response in donor SC2 was initially Antibodies directed against the surface markers CD27 and CD57 were used to stain tetramer-positive CD8 + lymphocytes. CD27 is a member of the tumour necrosis factor receptor superfamily ; it is up-regulated on initial activation of T cells, but is almost undetectable on cells subjected to long-term stimulation [54, 55] . CD57 is a carbohydrate antigen which is highly conserved across diverse species and is expressed principally in T cells that have undergone chronic expansion [56] . Representative data from patient SC12 are shown. In the early period, almost all Nef-specific CD8 + cells stained with CD27, suggesting that these cells were acutely stimulated. This is consistent with the clinical data. Subsequently, the proportion of tetramer-positive CD8 + lymphocytes expressing CD27 declined with time. In contrast, CD57 was expressed on a minority of tetramer-positive CD8 + lymphocytes during the early phase of infection. There was a steady increase in the percentage of CD57 + antigen-specific cells with time. Phenotyping of the FLRGRAYGL-and ELRSRYWAI-specific CD8 + lymphocyte populations showed a small increase in the number of these cells expressing CD27 during the acute period of seroconversion ; this was not sustained. The proportion of CD57 + cells in these populations increased slightly over time, although this change was minimal compared with that observed in the Nef-specific CD8 + lymphocytes (results not shown). In patient SC11, there was an increase in CD27 and a decrease in CD57 surface expression within the Nef-specific CD8 + cell population at 233 DFOSx ; this suggests the emergence of newly stimulated antigen-specific CD8 + lymphocytes following discontinuation of therapy (results not shown).
detected in standard cytotoxicity assays at 172 DFOSx ; it is not clear whether CD8 + lymphocytes with this specificity were present earlier, and further acutephase samples from this patient were unavailable for analysis. Early FLKEKGGLspecific expansions amounting to 0.54 % of the total CD8 + lymphocyte population at 36 DFOSx were detected in SC17 (see Figure 6) ; subsequently, this patient was lost to follow-up. Tetramers specific for HLA B8-restricted epitopes in Epstein-Barr virus nuclear antigen 3 (FLRGRAYGL) and influenza virus nucleoprotein (ELRSRYWAI) were used to control for the specificity of the observed changes in frequencies of HIV-1 Nef-specific CD8 + lymphocytes with time ; there was a small increase in the size of these antigen-specific populations during the seroconversion period in SC10, SC11 and SC12, but these changes were comparatively minimal (results not shown). All samples from each patient were processed in parallel to avoid discrepancies resulting from day-to-day variations in assay sensitivity. Each sample analysed contained 2i10 5 cells. For virus load, data points on the baseline are below the limit of detection (200 copies/ml).
replication rate of the viral population, the kinetics, breadth and potency of the CTL response, and the influence of other selection pressures operating in vivo [42] . Many of these variables cannot be quantified accurately in human studies, and therefore the limited antigenic variation in these patients may be unrelated to the administration of ART. However, in a further patient with untreated acute symptomatic primary HIV-1 infection (SC9), lower levels of tetramer-positive CD8 + cells specific for the HLA A2-restricted p17-18 Gag epitope SLYNTVATL (residues 77-85) in the peripheral blood (0.1-0.2 % of total CD8 + lymphocytes) were associated with the emergence of a dominant 3H escape mutant in the proviral population (D. A. Price and G. S. Ogg, unpublished work). Secondly, suppression of ongoing replication by ART may limit the capacity of the virus to evolve. Such ' restricted evolution ' has been observed previously in the HIV-1 pol gene in patients treated with ART later in disease [58, 59] . Thirdly, the selection pressure exerted by CTL activity, diminished by a decrease in antigenic load, may be subdominant in the presence of ART. Indeed, there are important qualitative differences in the selection pressures exerted by these anti-viral modalities. In this scenario, viral forms that escape from immunodominant CTL responses will not carry a significant selection advantage because all replicating viruses without drug-resistance mutations, regardless of their antigenic sequence, are likely to be equally affected by ART. Fourthly, there may be a positive association between viral latency and pretreatment antigenic sequence. Proviral forms that persist in the presence of ART may represent latent viruses that are relatively unaffected by drugs targeted at replication pathways. In addition, antigen expression may be negligible on the surface of cells carrying latent virus. The phenomenon of viral latency is well described, and it seems that viruses require distinct qualities in order to establish this state [58] [59] [60] [61] [62] [63] . Such viral ' compartmentalization ' may relate to a differential decay of proviruses following interruption of viral replication, such that administration of ART is associated with a tendency towards sequence homogeneity.
Discussion
Little is known of the immunological or clinical consequences of therapeutic intervention during primary HIV-1 infection. Although limited evidence suggests that virus-specific CD4 + lymphocyte proliferative activity may be preserved by early treatment [53] , the influence of ART on primary CTL responses has not been addressed. This project aimed to assess the impact of ART on the dynamic interactions between CTL and an evolving viral population during symptomatic primary HIV-1 infection. The necessarily small number of subjects studied reflects difficulties in the recruitment of such patients during a time of much emotional trauma, the logistics of serial sampling, and the labour-intensive nature of the work. In addition, there is potentially enormous variability in the specificity of early CTL activity. The identification of five patients with immunodominant CTL responses directed against the same epitope during primary HIV-1 infection represented the end product of a large screening exercise, and provided a unique opportunity to study anti-viral cellular immunity in comparable individuals both during the natural course of infection and in the presence of ART administered soon after diagnosis. However, the limited sample size restricts this work in its current form to a descriptive study in which the data must be regarded as preliminary and the summations speculative.
Tetrameric antigen complexes allow the accurate quantification ex vivo of CD8 + lymphocytes bearing TCRs specific for defined peptide-(HLA class I) ligands. A close temporal relationship between circulating levels of virus-specific CD8 + lymphocytes and HIV-1 RNA load was observed longitudinally with this methodology in patients receiving ART during primary HIV-1 infection. However, combination therapy did not eliminate these antigen-specific cells, despite prolonged suppression of plasma viraemia (Figure 7 ). This latter observation contrasts with recent data from patients treated during asymptomatic infection, in whom levels of virus-specific CD8 + lymphocytes declined to undetectable levels with falling virus load [64] . Early administration of ART may therefore confer immunological benefits which allow the maintenance of a virusspecific CD8 + lymphocyte response in the presence of a markedly reduced antigenic load. However, although some studies suggest that peptide-(HLA class I) complexes identify only functionally active cells [65] , more recent work has challenged this assumption [57] . Further studies are therefore required to determine the nature of these persistent antigen-specific CD8 + lymphocyte populations in patients treated early with ART.
The observation that early treatment preserves antigenic determinants without the abolition of primary antigen-specific CD8 + lymphocyte responses is potentially important. Events occurring during the early phase of HIV-1 infection are thought to determine the subsequent equilibrium level of virus load that persists throughout the asymptomatic phase [66] [67] [68] [69] ; this, in turn, predicts outcome [70, 71] . In particular, the emergence of HIV-1 variants which escape CTL recognition has been associated with increased plasma viraemia and disease progression [15, 44, 72] . During primary infection in patients with certain HLA haplotypes, immature oligospecific CTL responses directed against mutationally tolerant epitopes provide conditions conducive to viral immune escape [31, 44] ; if intervention with ART does limit HIV-1 evolution during this period, then such modification of early events may permit enhanced immune control of virus replication in the event of subsequent discontinuation of therapy. However, this is tempered by the degree to which ART affects the development of a mature CTL response. A combined approach, in which therapeutic vaccination designed to stimulate a polyvalent CTL response to biologically constrained antigenic regions is utilized in conjunction with early chemotherapeutic suppression of viraemia, may be optimal. Further studies are required to determine whether the theoretical advantages of early treatment translate into improved clinical outcome.
OVERVIEW
The demonstration that CTL exert selection pressure on the viral population during the natural course of HIV-1 infection indicates that these effector cells comprise a significant component of anti-retroviral immunity. Subsequent supporting evidence has come from two key studies. In the first, tetrameric peptide-(HLA class I) complexes were used to define an inverse correlation between circulating levels of antigen-specific CD8 + lymphocytes and plasma HIV-1 RNA load [73] . Mathematical models based on the assumption that CTL control viral replication in vivo predict exactly such a relationship [74, 75] . More recently, the critical role of CD8 + lymphocytes as mediators of protection against disease was demonstrated directly in the simian immunodeficiency virus model of AIDS using specific cellular depletion protocols [76] .
Coincidentally with the emergence of compelling evidence that CTL comprise a key facet of protective immunity against HIV-1, the development of peptide-(HLA class I) tetrameric complexes has provided a novel and potent methodology with which to study these effector cells [48] . Studies correlating clinical outcome with qualitative and quantitative aspects of the cellular immune response, and the relationship of these variables to treatment with anti-retroviral agents, may rapidly further our understanding of the natural history of HIV-1 infection and allow the rationalization of therapeutic interventions in the near future.
METHODS
The experimental procedures used in this work are described in [11] , [29] and [31] .
